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Background: We have previously shown that cell death is a pathophysiologic
consequence of ischemia-reperfusion and that interleukin-10 gene therapy improves
the function of transplanted lungs. Interleukin-10 downregulates the inflammatory
response and can inhibit apoptosis. The objective was to determine whether donor
lung transfection with the interleukin-10 gene ameliorates lung dysfunction by
decreasing cell death after transplantation.
Methods: Single lung transplants were performed in 3 groups of rats (n  5 each):
AdhIL-10, transtracheal administration of Ad5E1RSVhIL-10 (5  109 pfu); EV,
empty vector; and VD, vector diluent (3% sucrose). After in vivo transfection, donor
lungs were excised, stored at 4°C for 24 hours, and then transplanted. After 2 hours
of reperfusion, lungs were flushed with trypan blue and fixed. TUNEL staining was used
for the detection of apoptosis. This combined staining technique allows one to determine
the mode of cell death by distinguishing apoptotic dead cells from necrotic dead cells.
Results: Lung function was superior in the interleukin-10 group (P  .0001) vs the
EV and VD group (PaO2: 240  31 mm Hg vs 98  17 mm Hg vs 129  11 mm
Hg, respectively). Although the total number of dead cells (as percent of total cells)
was similar in all groups (32.7%  3.2%, 30.2%  2.5%, and 30.3%  3.8%),
interestingly, apoptosis was highest in interleukin-10 lungs (9.7  1.9 vs 2  1.9
and 1.8  2, P  .0001), and necrosis was lowest in the interleukin-10 group (20.6
 5.7 vs 28.3  3.1 and 30.3  4.2, P  .01).
Conclusions: AdhIL-10 gene transfection improves function of transplanted lungs.
Although the total number of cells dying as a result of the transplant process did not
change, the mode of cell death appears to have been modified. It is possible that
AdhIL-10, by decreasing proinflammatory cytokine production, ameliorates the
overall injury and preserves the ability of damaged cells to undergo a more quiescent
and less tissue-damaging mode of cell death—apoptosis, rather than necrosis.
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Lung transplantation is now accepted as astandard treatment modality for patientswith a number of end-stage lung diseases.1The long-term outcome after clinical lungtransplantation, however, is still not satisfac-tory, with a current 5-year survival of only
approximately 55%.2
It is clear that an improved understanding of the under-
lying mechanisms of the injury that is inflicted on pulmo-
nary grafts by ischemia, the transplant process itself, and
reperfusion of the transplanted lung—referred to as isch-
emia-reperfusion (IR) injury—is required. In examining
processes related to the induction of cell death in human
lungs during the transplantation period, we have previously
shown that approximately 30% of graft cells die within the
first 2 hours after graft reperfusion by “programmed cell
death” or apoptosis, whereas almost no signs of apoptosis
occurred in same lungs neither during 1 to 6 hours of cold
ischemia before the transplant nor during the implantation
process.3 This degree of cell death was seen even in patients
who did very well after lung transplantation.
Having discovered this remarkable loss of cells in trans-
planted lungs, which has also been described to various
degrees in other solid organs after transplantation, such as
the liver,4 kidney,5 and the heart,6 in a second study we
attempted to answer the question of what determines the
mode of cell death after IR injury in transplanted lungs and
how various factors such as ischemic time might influence
the amount of cell death that occurs. In a rat lung transplant
model, we determined that apoptosis is the predominant
mode of cell death in transplanted and reperfused lungs after
short and clinically relevant ischemic times (6-12 hours),
whereas in transplanted lungs after extended cold ischemic
periods (18 and 24 hours) necrosis is the predominant mode
of cell death with almost no apoptosis. The total amount of
dead cells in grafts, however, was similar in all study lungs.7
Interestingly, the amount of necrotic cells negatively corre-
lated with posttransplant graft function, but the degree of
apoptosis did not.7
From this study we learned that severe graft injury,
experimentally induced by a prolonged pretransplant graft
ischemic period, appears to be associated with severe cell
damage with no ability for the damaged cell to recover. The
severely injured cells undergo an uncontrolled and undi-
rected pathway to death, which is necrosis. The cell mem-
branes disrupt, intracellular proteins are released in the
surrounding tissue, and a massive inflammatory response is
initiated that affects neighboring healthy cells, which may
be secondarily injured and may also undergo cell death. In
case of milder IR injury, such as in lungs after short isch-
emic times, however, the injured cells appear to have pre-
served their ability to either recover or, if unable to recover,
to undergo the more quiescent mode of cell death—apopto-
sis—by initiating internal genetic suicide programs, which
follow complex pathways.8
In another study, we transfected donor rat lungs transtra-
cheally in vivo with adenoviral vectors carrying the gene
that encodes for the human anti-inflammatory cytokine in-
terleukin 10 (IL-10), also named cytokine release inhibitor
factor. Indeed, we were able to demonstrated that IR injury
in IL-10-transfected lungs was significantly improved com-
pared with lungs that were transfected with the empty
vehicle or the vehicle diluent only.9 This positive effect was
seen in physiologic lung function, histologic examination,
and the expression of the proinflammatory cytokines inter-
feron- (IFN-) and tumor necrosis factor- (TNF-),
which are early-onset mediators of IR injury.9 The fact that
IL-10 gene therapy improves the function of the trans-
planted lung having been demonstrated, the goal of the
current study was to determine whether this intervention
had any effect on the degree or mode of cell death associ-
ated with IR injury in lung transplantation.
Methods
Animals
Experiments were performed in male inbred (250-350 g) Lewis
rats (Charles River Inc, Montreal, Quebec, Canada). All animals
received care in compliance with the Principles of Laboratory
Animal Care formulated by the National Society for Medical
Research, the Guide for the Care and Use of Laboratory Animals
(NIH Publication No. 85-23, Revised 1985, US Government Print-
ing Office, Washington, DC 20402-9325), and the Guide to the
Care and Use of Experimental Animals formulated by the Cana-
dian Council on Animal Care. The experimental protocol was
approved by the Animal Care Committee of the Toronto General
Hospital Research Institute.
In Vivo Transfection Procedure
For the in vivo gene transfection procedure, donor animals were
anesthetized in a halothane chamber, orotracheally intubated with
a 14-gauge intravenous cannula, and connected to a volume-
controlled ventilator (Harvard Rodent Ventilator, model 683,
South Natick, Mass). All animals were ventilated with an inspired
oxygen fraction (FIO2) of 1.0 and a tidal volume of 10 mL/kg at 80
breaths/min.
A 1-mL syringe containing 0.5 mL of the transfection solution
was connected to the lateral outlet of a 3-way stopcock placed in
the circuit at the endotracheal catheter. For intratracheal injection,
the ventilator outlet of the 3-way stopcock was closed and the
solution was injected. Ventilation was then continued until the
animal resumed spontaneous breathing (approximately 60 to 90
seconds after intratracheal injection). All transfected animals were
kept in microisolators for 24 hours until graft retrieval. Food and
water was supplied ad libitum.
Lung Transplantation Procedure
Harvest and storage. We used a rat left single lung transplant
model. Donor rats were anesthetized by an intraperitoneal injection
of 1 mL of sodium pentobarbital (Somnotol, MTC Pharmaceuti-
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cals, Cambridge, Ontario, Canada) and intubated through a trache-
ostomy with a 14-gauge intravenous catheter. The tracheostomy
tube was then connected to a volume-controlled ventilator (Har-
vard Rodent Ventilator, model 683) and the animals were venti-
lated at a rate of 70 breaths/min, tidal volume of 10 mL/kg, FIO2 of
1.0, and a positive end-expiratory pressure (PEEP) of 2 cm H2O.
After this, a median laparo-sternotomy was performed and 300
USP units of heparin (Hepalean, Organon Teknika, Toronto, On-
tario, Canada) was injected into the inferior vena cava (IVC). After
a period of 5 minutes, 0.5 mL of arterial blood was taken from the
abdominal aorta for baseline blood gas analysis.
For the retrieval of the heart-lung block, the IVC was incised,
the left atrial appendage was excised, and a 14-gauge intravenous
catheter was placed into the main pulmonary artery (PA) through
an anterior incision in the right ventricular outflow tract. The lungs
were then flushed through this catheter with 20 mL of low-
potassium dextran glucose (LPDG) preservation solution (Perfa-
dex, Biophausia, Uppsala, Sweden) containing 500 g/L of pros-
taglandin E1 (PGE-1, Prostin VR, Upjohn, Don Mills, Ontario,
Canada) from a height of 30 cm. This is the same preservation
protocol that is currently used in our clinical lung transplant
program.9 Immediately after the lungs were flushed, the tracheos-
tomy tube was clamped after inspiration to preserve the lungs in
the inflated state. The heart-lung block was then removed and
placed in iced LPDG at 4°C. The left lung was prepared for
transplantation with the placement of three 14-gauge cuffs into the
left PA, left pulmonary vein (PV), and the left main bronchus
(MB), respectively. Left lungs were placed into 40 mL of LPDG at
4°C for 24 hours before transplantation.
Transplantation. Recipient animals were anesthetized and a
tracheostomy was performed as described for the donor animals.
The recipient animals were ventilated with a gas mixture of 75%
oxygen and 25% room air at a rate of 70 breaths/min and tidal
volume 10 mL/kg. A left thoracotomy was performed through the
fifth intercostal space. The left lung was mobilized by dividing the
pulmonary ligament. The hilar structures were then dissected free.
The left PA, PV, and MB were identified and clamped with
microsurgical aneurysm clamps. A ventral incision was made in
each of these structures. The cuffs on the donor lung structures
were placed into the corresponding recipient structures through
each incision. The anastomoses were secured with 7-0 polypro-
pylene ties. The implantation time, or warm ischemia time, was
standardized at 20 minutes; this is the period when the deflated
donor lung is in the chest at body temperature and the anastomotic
procedure is underway. After the standardized 20-minute period of
warm ischemia, the transplanted lung was reinflated after removal
of the MB clamp and blood was reintroduced by unclamping first
the PV, then the PA. The animal was ventilated with an FiO2 of 1.0
at a rate of 70 breaths/min, tidal volume of 10 mL/kg, and PEEP
of 2 cm H2O during the 2 hours of the reperfusion period. One
minute into the reperfusion period, each animal received 1 mL of
0.9% normal saline solution intraperitoneally for volume replace-
ment. Heparin was not given to the recipient animals, because it is
not routinely administered to lung transplant patients before graft
reperfusion. Each animal was covered during the reperfusion pe-
riod to prevent hypothermia. Two hours after graft reperfusion, 0.5
mL of blood was taken from the left PV of the transplanted lung
distal to the cuff anastomosis for blood gas analysis.
Tissue Treatment
All study lungs were flushed for 5 minutes with 20 mL of a 500
mol/L trypan blue (Sigma Chemical Co, St. Louis, Mo) solution
through the main PA, followed by 20 mL of 0.9% normal saline
solution and 10 mL of 4% paraformaldehyde. Trypan blue was
dissolved in Krebs-Henseleit buffer (pH 7.4; Sigma Chemical Co).
The lungs were then fixed in 10% formalin. The middle third of the
left lungs was used for histologic examination as that section is
representative of peripheral and central parenchymal areas.
Histologic Evaluation and Viability Assessment: Triple
Staining Technique
The triple staining technique for the quantification of apoptotic and
necrotic cells as compared to all nucleated graft cells (dead and
alive) in the same microscopic section has been previously de-
scribed.7
In brief, formalin-fixed lung tissues were embedded in paraffin
and cut into 4-m tissue slices. These were mounted onto saline-
treated glass slides for histologic assessment.
Apoptosis detection by in situ terminal deoxynucleotidyl trans-
ferase (TdT)-mediated dUTP nick end-labeling (TUNEL) was
undertaken using the ApopTag Kit (Oncor, Gaithersburg, Md)
according to the manufacturer’s instructions. Sections were depar-
affinized and rehydrated. Protein digestion was carried out by
application of proteinase K (20 g/mL) to the slides for 15 minutes
at room temperature followed by 4 washes in distilled water for 2
minutes each. Equilibration buffer was applied to the sections and
these were incubated in a humidified chamber for 3 minutes. The
sections were then incubated with TdT enzyme in a humidified
chamber at 37°C for 1 hour. This method is based on the enzymatic
ability of TdT to catalyze a template-independent addition of
deoxyribonucleotide triphosphate to the 3'-OH ends of double- or
single-stranded DNA. Anti-digoxigenin-fluorescein was applied to
the sections and these were then incubated in a humidified cham-
ber for 30 minutes at room temperature. The sections were then
washed with phosphate-buffered saline, and antifade containing
propidium iodide (PI) (Oncor, Gaithersburg, Md) was applied for
nuclear staining.
TUNEL-stained tissue sections were examined with fluorescent
microscopy. First, the PI staining (red) was examined through a
520-nm filter at a magnification of 100. PI stains (red) all
nucleated cells (alive, necrotic, and apoptotic) in the same manner.
The magnification was increased to 400 and a color photomi-
crograph was taken. Then, the same area viewed for the PI staining
was similarly examined for apoptotic staining (bright green) using
a 590-nm filter at a magnification of 400. After a color photomi-
crograph was taken through this filter system, the filters and the
ultraviolet light were turned off and a third picture of the same area
was taken to detect the trypan blue stain (dead cells) with standard
light microscopy. Two randomly chosen areas from each slide
were examined using this triple staining method.
The cell counts were performed by 2 researchers in a blinded
fashion. The slides were projected onto a grid comprised of 12
fields so that the cells could be counted. Six randomly chosen
fields were used. These 6 fields were used for all study slide
counts. PI-stained cells were counted first, followed by TUNEL-
positive cells, and finally the trypan blue–stained cells. Only cells
that could clearly be identified as individual cells were counted as
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cells. If they did not fulfill this criterion, they were considered to
be background staining.
The PI-stained count represents the total number of nucleated
graft cells (total cells: alive necrotic apoptotic). The TUNEL-
positive count represents the number of apoptotic cells. The trypan
blue count identifies the number of dead cells (necrotic  apopto-
tic). Therefore, the trypan blue count (necrotic  apoptotic) minus
the TUNEL-positive count (apoptotic) equals the number of ne-
crotic cells. The numbers of necrotic and apoptotic cells are given
as percentages of the total number of cells (PI-stained count).
Optimization of hIL-10 Gene Transfection and
Expression in Donor Lungs
IL-10 gene transfection of donor lungs and expression of the
transfected protein were optimized in our previous studies on in
vivo adenovirus-mediated gene transfection through the transtra-
cheal route.9-12
Generation of Recombinant Adenovirus Expressing
Human IL-10
Adenoviral vectors (serotype 5) containing the human IL-10 gene
with an RSV promoter (Ad5RSVhIL-10) and “empty” vectors
(Ad5BGL2) were constructed at the Gene Transfer Vector Core of
the University of Iowa College of Medicine, Iowa City, Iowa. The
hIL-10 adenoviral construct will be referred to as “AdhIL-10” and
the Ad5BGL2 will be referred to as “empty vector.”
Human IL-10 (hIL-10) cDNA was obtained by polymerase
chain reaction (PCR) with 5' and 3' flanking primers (5'-hIL-
10BamHI:5'-CGCGGATCCCATGCACAGCT-CAGCACTG-3';
3'-hIL-10BamHI:5'-CGCGGATCCGCCACCCTGATGTCTCAGT-
3'), using the clone pSRhIL-10 as template (kindly provided by E.
Field, University of Iowa). The PCR product was cloned, using the
BamHI restriction-site tails added to the oligonucleotide sequences, in
a shuttle plasmid (pAdRSV4). This shuttle plasmid contains the Rous
sarcoma virus promoter, the SV40-poly A signal, and the genomic
adenoviral sequences from 0 to 1 and 9 to 16 map units of human
adenovirus type 5. Recombinant adenovirus expressing IL-10 was
generated by homologous recombination between pAdRSVhIL-10
and human adenovirus serotype 5 derivative d1309, using standard
methods.13 AdBGL2 has the same viral backbone as AdRSVhIL-10.
In Vitro and in Vivo Evaluation of hIL-10 Bioactivity
after Ad5RSVhIL-10 Gene Transfer
An in vitro functional assay for hIL-10 was performed by Gud-
mundsson and colleagues at the University of Iowa College of
Medicine to test the activity of Ad5RSVhIL-10 on the basis of the
ability of IL-10 to inhibit the synthesis of IFN- by lectin-stimu-
lated spleen cells.13 The in vitro study showed that
Ad5RSVhIL-10 is bioactive in vitro, and inhibits IFN- expression
in lectin-stimulated murine spleen cells in a dose-dependent man-
ner. To test the bioactivity of Ad5RSVhIL-10 in vivo, IL-10
knockout (KO) mice were injected with 5  108 pfu of
Ad5RSVhIL-10 or AdRSVLacZ via a tail vein. Six days later
hIL-10 levels in blood were detected by ELISA. In a separate
experiment, IL-10 KO mice that received intravenous administra-
tion of Ad5RSVhIL-10 survived after intravenous lipopolysaccha-
ride injection, whereas IL-10 KO mice that received AdRSVLacZ
died of the endotoxin, which demonstrates the bioactivity of
Ad5RSVhIL-10 in vivo.
Measurement of Lung Graft Function
Graft function was assessed by PaO2 levels in blood taken from the
graft pulmonary vein at the completion of the 2-hour reperfusion
period under direct vision with a heparinized syringe.
Statistical Analysis
All data are expressed as mean  SD. A 1-way analysis of
variance (ANOVA) was used to determine statistical significance.
When the test of equal variance or the normality test failed a
Kruskal-Wallis 1-way ANOVA on ranks was performed. When
statistical significance was reached, it was followed by a post hoc
analysis using the Student-Newman-Keul method. The SigmaStat
software package version 1.0 (Jandel Scientific, San Rafael, Calif)
was used for all statistical analyses.
Results
Graft Function
Donor and recipient rats were size-matched in study groups.
All animals in this study survived for the individual study
periods. At the completion of the 2-hour reperfusion period,
blood samples were taken from the pulmonary graft vein
and analyzed for the partial pressure of oxygen (PaO2). The
ability of a transplanted lung to oxygenate blood remains a
critical measurement for the evaluation of posttransplant
pulmonary graft function.
The mean PaO2 level in arterial blood from donors in all
3 study groups was 572  41 mm Hg. The donor PaO2
levels were not significantly different among the individual
study groups. After the completion of the 2-hour reperfusion
period, PaO2 levels in IL-10 lungs were significantly higher
(P  .0001) than in empty vector (EV) and vector diluent
(VD) lungs (240  31 vs 98  17 mm Hg and 129  11
mm Hg, respectively, Figure 1).
Figure 1. In vivo transtracheal adenoviral mediated IL-10 gene
transfection of donor lungs improves posttransplant lung function.
Study groups: EV, empty vector; VD, vector diluent; IL-10, adeno-
virus-mediated interleukin-10. *P  .0001 versus other groups.
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Cell Death
We have previously described the time course of apoptosis
induction in transplanted lungs during ischemia and in the
early phase after transplantation.3 We have further shown
that the mode of cell death (apoptosis/necrosis) in lungs
after transplantation is dependent on the length of the cold
ischemic graft preservation time (CIT) before transplanta-
tion in that apoptosis appears after transplantation and
reperfusion in lungs that have been stored for relatively
short periods of CIT, whereas necrosis is the predominant
mode of cell death in lungs after extended CIT.7 We also
demonstrated that necrosis, but not apoptosis, correlates
with posttransplant lung function.7 Cox has previously dem-
onstrated that IL-10 enhances the resolution of pulmonary
inflammation in vivo by promoting apoptosis of neutro-
phils.14 Furthermore, IL-10 has an inhibitory effect on TNF-
–induced programmed cell death, as shown by Rojas and
associates.15
Apoptosis levels in the EV (1.8%  2%) and VD (2.0%
 1.9%) group in this study were as low as seen in our
previous study after similar CIT, when necrosis was the
predominant mode of cell death.7 In the IL-10 group, how-
ever, apoptosis levels reached 9.7%  1.9% of total graft
cells, which was significantly different than the other 2
study groups (P  .0001). This in fact does not necessarily
support a proapoptotic effect of IL-10. Rather, it suggests
that IL-10 reduced the injury in lungs after prolonged pres-
ervation and transplantation and preserved the ability of
damaged graft cells to undergo a less tissue destructive
mode of cell death (apoptosis) as compared with necrosis,
which causes further inflammation and tissue injury. Note
that the total number of cell that died (through apoptosis or
necrosis) was constant in all groups (32.7%  3.2% in EV,
30.2% 2.5% in VD and 30.3% 3.8% in IL-10 lungs) as
depicted in Figure 2. The number of necrotic cells was
lowest in IL-10 lungs (20.6%  5.7%) compared with VD
lungs (28.3% 3.1%) and EV lungs (30.3% 4.2%), (P
.01).
Discussion
IR injury remains a significant problem and can result in
pulmonary failure, multiorgan failure, and death after lung
transplantation. Clinical and experimental studies have
identified many of the mediators that are involved in the
regulation of pulmonary IR injury.16,17
We have previously described the role that apoptosis
plays in lung transplantation.8 Ischemia has been shown to
be a potential inducer of apoptosis.18 Because apoptotic
cells in an organ system are usually phagocytosed by mac-
rophages before their membranes break down and intracel-
lular enzymes are released, this mode of cell death does not
lead to significant tissue inflammation, which is character-
istically prominent with necrosis.18 In human lungs, we
have previously shown that apoptosis does not occur in
grafts during cold or warm ischemia. In the early phase after
graft reperfusion, however, the number of apoptotic graft
cells increased to 34% of cells.3 As a consequence of this
novel observation in lung transplantation, we have chosen
to focus our efforts on the regulatory mechanisms that are
involved in this dramatic loss of cells in lung grafts with the
ultimate hope to develop strategies to prevent cell death in
this setting.
However, we have demonstrated that, in addition to
apoptosis, cellular necrosis also plays a very important, if
not more important, role in posttransplant graft function and
that the mode of cell death (apoptosis or necrosis) after
transplantation is dependent on the length of ischemic graft
preservation before lung transplantation.7 Interestingly, the
amount of necrotic cells in transplanted lungs negatively
correlated with posttransplant graft function, whereas the
amount of apoptosis did not. This intriguing finding sug-
gests that the 2 different modes of cell death differentially
affect overall graft function. This is consistent with the
general understanding that apoptosis is a relatively “quies-
cent” form of cell death as compared with necrosis, which
induces significant inflammation and cytokine release. Ob-
viously, organ transplantation at this stage is not possible
without some injury to the graft or graft cells. Modern
preservation strategies in clinical lung transplantation con-
tinue to focus on the reduction of graft preservation injury.19
However, our experimental and clinical observations sug-
gest that graft cell injury still remains a significant problem.
Ideally, we strive to minimize all cell death related to the
injury of transplantation. However, if the process of trans-
plantation inflicts a degree of injury such that an inevitable
amount of cell death must occur, it would seem to be
Figure 2. IL-10 in vivo donor lung transfection leads to a switch
from necrosis to apoptosis in transplanted and reperfused lungs.
Note that the total number of dead cells is similar in all groups,
but that the AdIL-10 group has significantly less necrosis and
more apoptosis (*P  .0001; #P  .01) compared with the other
groups.
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protective to the organism overall if cells underwent apo-
ptosis rather than necrosis.
IR injury is an insult to the transplanted lung that occurs
at a predictable time point. This lends itself to the applica-
tion of preventive strategies that can be applied before the
insult occurs. We have previously described the protective
effect of adenovirus-mediated transtracheal transfection of
the human IL-10 gene to donor lungs in vivo on posttrans-
plant lung function in the early phase after graft reperfu-
sion.9 This strategy uses the graft’s own cellular machinery
to upregulate expression of a protective gene and to produce
the desired protein like human IL-10 in the current study,
such that it is available in appropriate protective quantities
at the time of the initiation of the insult.
From experimental studies, it is evident that proinflam-
matory cytokines such as TNF- and IFN-, produced by
macrophages, epithelial cells, and monocytes, play impor-
tant key roles in IR injury in lung transplantation.20 We
have shown that IL-10 gene transfection of donor lungs
leads to a significantly reduced synthesis and release of
proinflammatory cytokines in transplanted lungs after 24
hours of cold preservation9 and that, as a result of the severe
insult during 24-hour preservation, the majority of dead
graft cells after transplantation are necrotic.7
Because IL-10 is widely known to inhibit the release of
these proinflammatory cytokines, we hypothesized that re-
duction of the inflammatory response by IL-10 gene therapy
in this rat model of severe posttransplant lung injury might
affect the amount of cell death and may improve lung
function. What we have found is indeed intriguing and not
what one might have expected. Although the total number
of dead cells does not change in the IL-10–treated group
compared with the control groups, in a third of all dead graft
cells the mode of cell death was switched from necrosis to
apoptosis in the IL-10-transfected lungs. This suggests that
possibly by the reduction of the severity of the inflammatory
response to IR injury, IL-10 gene upregulation significantly
protected the graft such that a significant amount of cells,
which were perhaps irreversibly damaged beyond recovery,
retained their ability to undergo apoptosis, rather than ne-
crosis.
This study once again underscores the importance of
improving our understanding of the mechanisms of cell
death in transplantation medicine. In future studies the un-
derlying regulatory pathways of the observed switch from
necrosis to apoptosis need to be clarified in greater depth to
develop more specific approaches to the prevention of cell
death in lung grafts and to prolong the maximally tolerable
ischemic time for lungs, which eventually will help to
increase the number of donor organs available and the
success of clinical lung transplantation.
In summary, transtracheal transfection of the lung can be
used to genetically modify donor lungs to express a desired
protein before transplantation and graft reperfusion. We
have shown that the in vivo transtracheal delivery of the
gene that encodes for IL-10 to donor rat lungs significantly
improves graft function after lung transplantation. This
improved function is associated with a switch from cel-
lular necrosis to apoptosis in a significant number of graft
cells.
The viruses used in this study (AdhIL-10 and AdBGL-2) were
prepared by the Gene Vector Core (Director: B. Davidson, PhD) of
the University of Iowa Faculty of Medicine, Iowa City, Iowa. We
also acknowledge the professional assistance by Dr Beverly Da-
vidson (Gene Vector Core of the University of Iowa Faculty of
Medicine, Iowa City, Iowa) for her advice on planning the exper-
iments and discussing the results and Dr Ioan Mates (DVM) for his
support in conducting the animal procedures.
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Discussion
Dr Frank W. Sellke (Boston, Mass). With the total number of
dead cells the same between groups, how do you explain the
dramatic functional difference? Second, did you evaluate the ex-
pression of inflammatory cytokines such as TNF- and IL-2 to see
whether the IL-10 transfection had an effect in this area?
Dr Fischer. Regarding the second question, we have measured
the expression of TNF-, not in this study but in the first IL-10
study that I mentioned, and TNF- and other proinflammatory
cytokines were indeed significantly lessened regarding their ex-
pression.
The first question was regarding lung function, why we see
such a difference in lung function even though we have the same
amount of cell death. I think it is not only dependent on the number
of cells that are there but also on the inflammatory response around
the cells. A cell may be in an area that is very inflamed. These
areas may not be well perfused with blood, and that might be a
reason for this huge difference in lung function.
Dr Sellke. Did you evaluate the inflammatory response histo-
logically? Was there a difference between the groups? Did you
observe more inflammation and membrane thickening, which may
impair lung function in the absence of cell death?
Dr Fischer. We saw much more hemorrhage on simple hema-
toxylin-eosin staining, and we saw much more edema. Also, wet/
dry weight ratios indicated a significant difference in the groups.
Dr G. Alexander Patterson (St. Louis, Mo). I have a follow-up
question to Dr. Sellke’s. With 30% of cells dead, it is hard to
understand that the lung is actually functioning so well. Which
cells are dead? You put the animals to death 2 hours after the
reperfusion. Do you have any data to indicate what the story would
be if you put the animals to death at 1 hour or 12 hours or 24
hours? It seems like a very brief snapshot at one time point.
Dr Fischer. Thank you very much. Your question regarding
which cells undergo cell death is a very important one. First, we
were surprised by the high number of dead cells that we discovered
in transplanted human lungs. We looked at the dead cells by
electron microscopy and found that the vast majority of dead cells
or apoptotic cells were alveolar type II cells. We saw some
interstitial cells and we also saw apoptotic neutrophils, which may
not be native cells but immigrated cells.
Regarding the second question, we have looked at later out-
come after 1 day of transplantation and reperfusion in the IL-10
study. We found, first, that gene expression continued after trans-
plant, either cold preservation or transplantation, but we have not
looked at cell death at this moment after a day. It is a very
important point, and ongoing studies now are definitely focusing
on the question; whole lung with 30% dead cells recovers from this
dramatic injury, and I think that is a very important and complex
problem by itself. We have actually several ongoing studies fo-
cusing on this recovery story.
Dr Minoru Ono (Tokyo, Japan). I am worrying about the
suppression of the inflammatory cytokine protection induced by
IL-10. It has other proinflammatory cytokine effects. Did you
check the survival model using the IL-10 while in transfection? If
you did not check the survival model, do you have any idea about
the IL-10 effect on the infection of the transplanted lung?
Dr Fischer. Is your concern that the IL-10 expression does not
reduce the release or expression of proinflammatory cytokines?
Dr Ono. No. My concern is that IL-10 induction may cause the
suppression of the inflammatory cytokine expression, including
IL-6 or TNF- or IL-2. That may impair the resistance to infection
in the survival model.
Dr Fischer. In the first IL-10 study that I mentioned we
performed several survival studies in pilot studies, and we found
that the suppression of the inflammatory response by IL-10 gene
transfection continues until day 1 after transplantation. We have
not performed survival studies beyond the first day of reperfusion
because that is probably another point that has to be focused on,
which was not the initial question of our study. That is the only
information I can provide so far to your question.
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